Specific HRD tests help clarify the location for PARP inhibition in ovarian cancer
For patients with homologous relapse repair defect (HRD), PARP inhibitors may be an effective treatment for patients with ovarian cancer. PARP protectors such as olaparib (Lynparza), niraparib (Zej…
